Table 3.

Pharmacological management of patients with heart failure (HF) within 90 days after the initial skilled nursing facility admission, stratified by type of HF

	HFpEF (n = 51,162)	HFrEF (n = 41,340)	Unspecified HF (n = 58,457)
HF-related medications (%)
ACEIs/ARBs*	47.2	55.7	47.6
ACEIs	32.8	43.2	34.2
ARBs	16.3	14.7	15.2
EBBBs†	33.0	52.7	35.3
Aldosterone antagonists	10.6	17.4	11.0
Nitrates	19.8	24.3	18.2
Hydralazine	9.4	8.7	6.8
Loop diuretics	71.3	72.8	65.3
Thiazide diuretics	14.0	12.3	12.0
Potassium-sparing diuretics	2.1	1.5	1.7
Digoxin	12.9	20.4	15.5
Other cardiac medications (%)
Non-evidence-based β-blockers	38.1	28.2	31.9
Antiarrhythmic agents	9.0	14.1	9.3
Calcium channel blockers	39.1	22.8	30.7
Dihydropyridine	25.3	15.3	20.5
Diltiazem	12.1	6.7	8.9
Verapamil	1.7	0.8	1.3
Renin inhibitors	0.5	0.3	0.4
Anticoagulants	29.8	32.1	28.6
Statins	48.8	54.2	46.9

HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EBBB, evidence-based β-blocker.

^*5% of patients had claims for both ACEIs and ARBs and were counted in both ACEI and ARB subcategories, so the sum of ACEI/ARB is not equal the sum of ACEI and ARB subcategories;

^†Includes bisoprolol, carvedilol, and metoprolol succinate extended release.